Oxytocin and autism: A systematic review of randomized controlled trials

Journal of Child and Adolescent Psychopharmacology

Volumn 24, Issue 2, 2014, Pages 54-68

  Preti, Antonio ^a   Melis, Mariangela ^a   Siddi, Sara ^a   Vellante, Marcello ^a   Doneddu, Giuseppe ^b   Fadda, Roberta ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b BROTZU HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OXYTOCIN; PLACEBO; RISPERIDONE;

AUTISM; COMPULSION; DISEASE SEVERITY; DRUG MECHANISM; DRUG TOLERABILITY; EMOTION; FRAGILE X SYNDROME; GAZE; HUMAN; INTELLECTUAL IMPAIRMENT; IRRITABILITY; MULTICENTER STUDY (TOPIC); NONHUMAN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOGNITION; REVIEW; SOCIAL COGNITION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CHILD DEVELOPMENT DISORDERS, PERVASIVE; INTRANASAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; OXYTOCIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84897396537     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2013.0040     Document Type: Review

References (155)

1. Achenbach TM: Integrative Guide for the 1991 CBCL/4-18, YSR, and TRF Profiles. Burlington, VT: Department of Psychiatry, University of Vermont; 1991.
2. Adolphs R, Spezio M: Role of the amygdala in processing visual social stimuli. Prog Brain Res 156:363-378, 2006.
3. Alfirevic Z, Kelly AJ, Dowswell T: Intravenous oxytocin alone for cervical ripening and induction of labour. Cochrane Database Syst Rev 4:CD003246, 2009.
4. Aman MG, Singh NN, Stewart AW, Field CJ: The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-491, 1985.
5. American Psychiatric Association: Autism Spectrum Disorder. Proposed revision-APA DSM-5. American Psychiatric Association; January 26, 2011. Available at http://www.dsm5.org/ProposedRevision/Pages/proposedrevision.aspx? rid =94#. Accessed August 15, 2012.
6. Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S, Wang AT, Pepa L, Tanel N, Kushki A, Hollander E: Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism 3:16, 2012.
7. Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, Sirigu A: Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci USA 107:4389-4394, 2010.
8. Arndt TL, Stodgell CJ, Rodier PM: Theteratology of autism. Int J Dev Neurosci 23:189-199, 2005.
9. Asperger H: The 'autistic psychopathy' in childhood. Arch Psychiatr Nervenkr 117:76-136, 1944.
10. Bales KL, Perkeybile AM, Conley OG, Lee MH, Guoynes CD, Downing GM, Yun CR, Solomon M, Jacob S, Mendoza SP: Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles. Biol Psychiatry 74:180-188, 2013.
11. Baron-Cohen S: Empathizing, systemizing, and the extreme male brain theory of autism. Prog Brain Res 186:167-175, 2010.
12. Baron-Cohen S: Mind Reading the Interactive Guide to Emotions. London: Jessica Kingsley Publishers; 2007.
13. Baron-Cohen S, Wheelwright S: The Friendship Questionnaire: An investigation of adults with Asperger syndrome or high-functioning autism, and normal sex differences. J Autism Dev Disord 33:509-517, 2003.
14. Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I: The 'Reading the Mind in the Eyes' test revised version: A study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry 42:241-251, 2001.
15. Bartz JA, Zaki J, Bolger N, Hollander E, Ludwig NN, Kolevzon A, Ochsner KN: Oxytocin selectively improves empathic accuracy. Psychol Sci 21:1426-1428, 2010.
16. Bartz JA, Zaki J, Bolger N, Ochsner KN: Social effects of oxytocin in humans: Context and person matter. Trends Cogn Sci 15:301-309, 2011.
17. Baum KM, Nowicki S: Perception of emotion: Measuring decoding accuracy of adult prosodic cues varying in intensity. J Nonverbal Behav 22:89-107, 1989.
18. Baumgartner T, Heinrichs M, Vonlanthen A, Fischbacher U, Fehr E: Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 58:639-650, 2008.
19. Bethlehem RA, van Honk J, Auyeung B, Baron-Cohen S: Oxytocin, brain physiology, and functional connectivity: A review of intra-nasal oxytocin fMRI studies. Psychoneuroendocrinology 38:962-974, 2013.
20. Beversdorf DQ, Manning SE, Hillier A, Anderson SL, Nordgren RE, Walters SE, Nagaraja HN, Cooley WC, Gaelic SE, Bauman ML: Timing of prenatal stressors and autism. J Autism Dev Disord 35:471-478, 2005.
21. Bodfish JW, Symons FJ, Parker DE, Lewis MH: Varieties of repetitive behavior in autism: Comparisons to mental retardation. J Autism Dev Disord 30:237-243, 2000.
22. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL: Sniffing neuropeptides: A transnasal approach to the human brain. Nat Neurosci 5:514-516, 2002.
23. Borrow AP, Cameron NM: The role of oxytocin in mating and pregnancy. Horm Behav 61:266-276, 2012.
24. Burkett JP, Young LJ: The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction. Psychopharmacology 224:1-26, 2012.
25. Carson DS, Guastella AJ, Taylor ER, McGregor IS: A brief history of oxytocin and its role in modulating psychostimulant effects. J Psychopharmacol 27:231-247, 2013.
26. Carter MT, Scherer SW: Autism spectrum disorder in the genetics clinic: A review. Clin Genet 83:399-407, 2013.
27. Chevallier C, Kohls G, Troiani V, Brodkin ES, Schultz RT: The social motivation theory of autism. Trends Cogn Sci 16:231-239, 2012.
28. Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, Vestergaard M: Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 309:1696-1703, 2013.
29. Churchland PS, Winkielman P: Modulating social behavior with oxytocin: How does it work? What does it mean? Horm Behav 61:392-399, 2012.
30. Cohen J: Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
31. Constantino JN: The Social Responsiveness Scale. Los Angeles: Western Psychological Services; 2002.
32. Dadds MR, Hawes D, Merz S: The UNSW Facial Emotion Task. Sydney: Department of Psychology, University of New South Wales; 2004.
33. Dadds MR, Macdonald E, Cauchi A, Williams K, Levy F, Brennan J: Nasal oxytocin for social deficits in childhood autism: A randomized controlled trial. J Autism Dev Disord 2013 Jul 26 [Epub ahead of print].
34. De Dreu CK, Greer LL, Handgraaf MJ, Shalvi S, Van Kleef GA, Baas M, Ten Velden FS, Van Dijk E, Feith SW: The neuropeptide oxytocin regulates parochial altruism in intergroup conflict among humans. Science 328:1408-1411, 2010.
35. Declerck CH, Boone C, Kiyonari T: Oxytocin and cooperation under conditions of uncertainty: the modulating role of incentives and social information. Horm Behav 57:368-374, 2010.
36. Ditzen B, Schaer M, Gabriel B, Bodenmann G, Ehlert U, Heinrichs M: Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol Psychiatry 65:728-731, 2009.
37. Domes G, Heinrichs M, Gläscher J, Büchel C, Braus DF, Herpertz SC: Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry 62:1187-1190, 2007a.
38. Domes G, Heinrichs M, Kumbier E, Grossmann A, Hauenstein K, Herpertz SC: Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. Biol Psychiatry 74:164-171, 2013.
39. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC: Oxytocin improves "mind-reading" in humans. Biol Psychiatry 61:731-733, 2007b.
40. Domes G, Lischke A, Berger C, Grossmann A, Hauenstein K, Heinrichs M, Herpertz SC: Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 35:83-93, 2010.
41. Donaldson ZR, Young LJ: Oxytocin, Vasopressin, and the neurogenetics of sociality. Science 322:900-904, 2008.
42. Dove D, Warren Z, McPheeters ML, Taylor JL, Sathe NA, Veenstra-VanderWeele J: Medications for adolescents and young adults with autism spectrum disorders: A systematic review. Pediatrics 130:717-726, 2012.
43. du Vigneaud V: Oxytocin, the principal oxytocic hormone of the posterior pituitar gland: Its isolation, structure, and synthesis. Ex-perientia 2:9-26, 1955.
44. du Vigneaud V, Ressler C, Trippett S: The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. J Biol Chem 205:949-957, 1953.
45. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR: Publication bias in clinical research. Lancet 337:867-872, 1991.
46. Elsabbagh M, Mercure E, Hudry K, Chandler S, Pasco G, Charman T, Pickles A, Baron-Cohen S, Bolton P, Johnson MH: BASIS Team. Infant neural sensitivity to dynamic eye gaze is associated with later emerging autism. Curr Biol 21:22:338-342, 2012.
47. Falkmer T, Anderson K, Falkmer M, Horlin C: Diagnostic procedures in autism spectrum disorders: A systematic literature review. Eur Child Adolesc Psychiatry 22:329-340, 2013.
48. Farmer C, Thurm A, Grant P: Pharmacotherapy for the core symptoms in autistic disorder: Current status of the research. Drugs 73:303-314, 2013.
49. Feldman R, Gordon I, Zagoory-Sharon O: Maternal and paternal plasma, salivary, and urinary oxytocin and parent-infant synchrony: Considering stress and affiliation components of human bonding. Dev Sci 14: 752-761, 2011.
50. Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT: Social amnesia in mice lacking the oxytocin gene. Nat Genet 25:284-288, 2000.
51. Fombonne E: The epidemiology of autism: A review. Psychol Med 29:769-786, 1999.
52. Gabor CS, Phan A, Clipperton-Allen AE, Kavaliers M, Choleris E: Interplay of oxytocin, vasopressin, and sex hormones in the regulation of social recognition. Behav Neurosci 126:97-109, 2012.
53. Gimpl G, Fahrenholz F: The oxytocin receptor system: Structure, function, and regulation. Physiol Rev 81:629-683, 2001.
54. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability. Arch Gen Psychiat 46:1006-1011, 1989.
55. Gordon I, Martin C, Feldman R, Leckman JF: Oxytocin and social motivation. Dev Cogn Neurosci 1:471-493, 2011.
56. Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie I: Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 67:692-694, 2010.
57. Guastella AJ, Hickie IB, McGuinness MM, Otis M, Woods EA, Dis-inger HM, Chan HK, Chen TF, Banati RB. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology 38:612-625, 2013.
58. Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS: A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 34:917-923, 2009.
59. Guastella AJ, MacLeod C: A critical review of the influence of oxytocin nasal spray on social cognition in humans: Evidence and future directions. Horm Behav 61:410-418, 2012.
60. Guastella AJ, Mitchell PB, Dadds MR: Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry 63:3-5, 2008.
61. Guy W: ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ No ADM 76-338). Rockville, MD: United States Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
62. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ: GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383-94, 2011.
63. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, GRADE Working Group: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924-926, 2008.
64. Hall SS, Lightbody AA, McCarthy BE, Parker KJ, Reiss AL: Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology 37:509-518, 2012.
65. Heil KM, Schaaf CP: The genetics of Autism Spectrum Disorders-a guide for clinicians. Curr Psychiatry Rep 15:334, 2013.
66. Heinrichs BV, von Dawans B, Domes G: Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol 30:548-557, 2009.
67. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group, Cochrane Statistical Methods Group: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928, 2011.
68. Hobson R, Lee A: Hello and goodbye: A study of social engagement in autism. J Autism Dev Disord 28:117-127, 1998.
69. Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S: Oxytocin increases retention of social cognition in autism. Biol Psychiatry 61:498-503, 2007.
70. Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Ar-onowitz BR, Mosovich S: Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neu-ropsychopharmacology 28:193-198, 2003.
71. Howlin P, Goode S, Hutton J, Rutter M: Adult outcome for children with autism. J Child Psychol Psychiatry 45:212-229, 2004.
72. Hurlemann R, Patin A, Onur OA, Cohen MX, Baumgartner T, Metzler S, Dziobek I, Gallinat J, Wagner M, Maier W, Kendrick KM: Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. J Neurosci 30:4999-5007, 2010.
73. Insel TR: Oxytocin-a neuropeptide for affiliation: evidence from behavioral, receptor autoradiographic, and comparative studies. Psychoneuroendocrinology 17:3-35, 1992.
74. Ivell R, Kimura T, Müller D, Augustin K, Abend N, Bathgate R, Telgmann R, Balvers M, Tillmann G, Fuchs AR:The structure and regulation of the oxytocin receptor. Exp Physiol 86:289-296, 2001.
75. Izuma K, Matsumoto K, Camerer CF, Adolphs R: Insensitivity to social reputation in autism. Proc Natl Acad Sci USA 108:17302-17307, 2011.
76. Jacob S, Brune CW, Carter CS, Leventhal BL, Lord C, Cook EH Jr: Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism. Neurosci Lett 417:6-9, 2007.
77. Jesner OS, Aref-Adib M, Coren E: Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 1:CD005040, 2007.
78. Johnson CP, Myers SM: Identification and evaluation of children with autism spectrum disorders. Pediatrics 120:1183-1206, 2007.
79. Kanner L: Autistic disturbances of affective contact. Nerv Child 2:217-250, 1943.
80. Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H: Structure and expression of a human oxytocin receptor. Nature 356:526-529, 1992.
81. Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A: Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 25:11, 489-11, 493, 2005.
82. Kiss A, Mikkelsen JD: Oxytocin-anatomy and functional assignments: A minireview. Endocr Regul 39:97-105, 2005.
83. Klein JT, Shepherd SV, Platt ML: Social attention and the brain. Curr Biol 19:R958-R962, 2009.
84. Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, Perrin JM, Ghandour RM, Singh GK, Strickland BB, Trevathan E, van Dyck PC: Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics, 124:1395-1403, 2009.
85. Kosaka H, Munesue T, Ishitobi M, Asano M, Omori M, Sato M, Tomoda A, Wada Y:Long-term oxytocin administration improves social behaviors in a girl with autistic disorder. BMC Psychiatry 12:110, 2012.
86. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E: Oxytocin increases trust in humans. Nature 435:673-676, 2005.
87. Kraemer HC, Kupfer DJ: Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 59:990-996, 2006.
88. Krueger DD, Bear MF: Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 62:411-429, 2011.
89. Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs M, Stout JC, Nathan PJ: Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. Int J Neuropsychopharmacol 14:1-14, 2011.
90. Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs M, Stout JC, Nathan PJ: Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharma-cology 35:2403-2413, 2010.
91. Landgraf R, Neumann ID: Vasopressin and oxytocin release within the brain: A dynamic concept of multiple and variable modes of neuro-peptide communication. Front Neuroendocrinol 25:150-176, 2004.
92. Landrigan PJ. What causes autism? Exploring the environmental contribution. Curr Opin Pediatr 22:219-225, 2010.
93. Lerer E, Levi S, Salomon S, Darvasi A, Yirmiya N, Ebstein RP: Association between the oxytocin receptor (OXTR) gene and autism: Relationship to Vineland Adaptive Behavior Scales and cognition. Mol Psychiatry 13:980-988, 2008.
94. Levine A, Zagoory-Sharon O, Feldman R, Weller A: Oxytocin during pregnancy and early postpartum: individual patterns and maternal-fetal attachment. Peptides 28:1162-1169, 2007.
95. Li X, Zou H, Brown WT: Genes associated with autism spectrum disorder. Brain Res Bull 88:543-552, 2012.
96. Libbey JE, Sweeten TL, McMahon WM, Fujinami RS: Autistic disorder and viral infections. J Neurovirol 11:1-10, 2005.
97. Lippert TH, Mueck AO, Seeger H, Pfaff A: Effects of oxytocin outside pregnancy. Horm Res 60:262-271, 2003.
98. Lischke A, Gamer M, Berger C, Grossmann A, Hauenstein K, Heinrichs M, Herpertz SC, Domes G: Oxytocin increases amygdala reactivity to threatening scenes in females. Psychoneuroendo-crinology 37:1431-1438, 2012.
99. Liu X, Kawamura Y, Shimada T, Otowa T, Koishi S, Sugiyama T, Nishida H, Hashimoto O, Nakagami R, Tochigi M, Umekage T, Kano Y, Miyagawa T, Kato N, Tokunaga K, Sasaki T: Association of the oxytocin receptor (OXTR) gene polymor-phisms with autism spectrum disorder (ASD) in the Japanese population. J Hum Genet 55:137-141, 2010.
100. Liu Y, Wang ZX: Nucleus accumbens oxytocin and dopamine interact to regulate pair bond formation in female prairie voles. Neuro-science 121:537-544, 2003.
101. Loup F, Tribollet E, Dubois-Dauphin M, Dreifuss JJ: Localization of high-affinity binding sites for oxytocin and vasopressin in the human brain. An autoradiographic study. Brain Res 555:220-232, 1991.
102. MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ: A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 36:1114-26, 2011.
103. MacDonald K, MacDonald TM: The peptide that binds: A systematic review of oxytocin and its prosocial effects in humans. Harv Rev Psychiatry 18:1-21, 2010.
104. Maglione MA, Gans D, Das L, Timbie J, Kasari C, Technical Expert Panel, HRSA Autism Intervention Research-Behavioral (AIR-B) Network: Nonmedical interventions for children with ASD: Recommended guidelines and further research needs. Pediatrics 130:S169-78, 2012.
105. Marsh AA, Yu HH, Pine DS, Blair RJR: Oxytocin improves specific recognition of positive facial expressions. Psychopharmacology (Berl) 209:225-232, 2010.
106. McCarthy MM, McDonald CH, Brooks PJ, Goldman D: An anxiolytic action of oxytocin is enhanced by estrogen in the mouse. Physiol Behav 60:1209-1215, 1996.
107. Mefford HC, Batshaw ML, Hoffman EP: Genomics, intellectual disability, and autism. N Engl J Med 366:733-743, 2012.
108. Melis MR, Argiolas A: Central control of penile erection: a re-visitation of the role of oxytocin and its interaction with dopamine and glutamic acid in male rats. Neurosci Biobehav Rev 35:939-955, 2011.
109. Mendelsohn NJ, Schaefer GB: Genetic evaluation of autism. Semin Pediatr Neurol 15:27-31, 2008.
110. Mens WB, Witter A, Van Wimersma Greidanus TB: Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): Half-times of disappearance of these neuropeptides from CSF. Brain Res 262:143-149, 1983.
111. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M: Oxytocin and vasopressin in the human brain: Social neuropeptides for translational medicine. Nat Rev Neurosci 12:524-538, 2011.
112. Miller G: Neuroscience. The promise and perils of oxytocin. Science 339:267-269, 2013.
113. Modi ME, Young LJ: The oxytocin system in drug discovery for autism: Animal models and novel therapeutic strategies. Horm Behav 61:340-350, 2012.
114. Munesue T, Yokoyama S, Nakamura K, Anitha A, Yamada K, Hayashi K, Asaka T, Liu HX, Jin D, Koizumi K, Islam MS, Huang JJ, Ma WJ, Kim UH, Kim SJ, Park K, Kim D, Kikuchi M, Ono Y, Nakatani H, Suda S, Miyachi T, Hirai H, Salmina A, Pichugina YA, Soumarokov AA, Takei N, Mori N, Tsujii M, Sugiyama T, Yagi K, Yamagishi M, Sasaki T, Yamasue H, Kato N, Hashimoto R, Ta-niike M, Hayashi Y, Hamada J, Suzuki S, Ooi A, Noda M, Ka-miyama Y, Kido MA, Lopatina O, Hashii M, Amina S, Malavasi F, Huang EJ, Zhang J, Shimizu N, Yoshikawa T, Matsushima A, Minabe Y, Higashida H: Two genetic variants of CD38 in subjects with autism spectrum disorder and controls. Neurosci Res 67:181-191, 2010.
115. Nakano T, Tanaka K, Endo Y, Yamane Y, Yamamoto T, Nakano Y, Ohta H, Kato N, Kitazawa S: Atypical gaze patterns in children and adults with autism spectrum disorders dissociated from developmental changes in gaze behaviour. Proc R Soc Lond B Biol Sci 277:2935-2943, 2010.
116. Oono IP, Honey EJ, McConachie H: Parent-mediated early intervention for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 4:CD009774, 2013.
117. Osterling JA, Dawson G, Munson JA: Early recognition of 1-year-old infants with autism spectrum disorder versus mental retardation. Dev Psychopathol 14:239-251, 2002.
118. OSU Research Unit on Paediatric Psychopharmacology: OSU Autism Rating Scale-DSM-IV (OARS-4). Columbus, OH: OSU Research Unit on Paediatric Psychopharmacology; 2005.
119. Pardo CA, Vargas DL, Zimmerman AW: Immunity, neuroglia and neuroinflammation involvement in schizophrenia and autism: Etiology, pathology and animal models. Behav Brain Res 204:313-321, 2005.
120. Patterson PH: Immune involvement in schizophrenia and autism: Etiology, pathology and animal models. Behav Brain Res 204:313-321, 2009.
121. Perry A, Bentin S, Shalev I, Israel S, Uzefovsky F, Bar-On D, Ebstein RP: Intranasal oxytocin modulates EEG mu/alpha and beta rhythms during perception of biological motion. Psychoneuroendocrinology 35:1446-1453, 2010.
122. Pfister HP, Muir JL: Influence of exogenously administered oxytocin on central noradrenaline, dopamine and serotonin levels following psychological stress in nulliparous female rats (Rattus norvegicus). Int J Neurosci 45:221-229, 1989.
123. Popik P, Vetulani J, van Ree JM: Low doses of oxytocin facilitate social recognition in rats. Psychopharmacology (Berl) 106:71-74, 1992.
124. Rai D, Golding J, Magnusson C, Steer C, Lewis G, Dalman C: Prenatal and early life exposure to stressful life events and risk of autism spectrum disorders: Population-based studies in Sweden and England. PLoS One 7:e38893, 2012.
125. Riem MME, Bakermans-Kranenburg MJ, Pieper S, Tops M, Boksem MAS, Vermeiren RRJM, Van Ijzendoorn MH, Rombouts SARB: Oxytocin modulates amygdala, insula and inferior frontal gyrus responses to infant crying: A randomized control trial. Biol Psychiatry 70:291-297, 2011.
126. Rilling JK, DeMarco AC, Hackett PD, Thompson R, Ditzen B, Patel R, Pagnoni G: Effects of intranasal oxytocin and vasopressin on cooperative behavior and associated brain activity in men. Psychoneuroendocrinology. 37:447-461, 2012.
127. Rosenthal R: The file drawer problem and tolerance for null results. Psychol Bull 86:638-641, 1979.
128. Sanna F, Argiolas A, Melis MR: Oxytocin-induced yawning: Sites of action in the brain and interaction with mesolimbic/mesocortical and incertohypothalamic dopaminergic neurons in male rats. Horm Behav 62:505-514, 2012.
129. Schopler EC, Reichler RJ, Renner BR: The Childhood Autism Rating Scale (CARS). Los Angeles: Western Psychological Services; 1988.
130. Skevington SM, Lotfy M, O'Connell KA: The World Health Organization's WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 13:299-310, 2004.
131. Skuse DH, Gallagher L: Dopaminergic-neuropeptide inter-actions in the social brain. Trends Cogn Sci 13:27-35, 2009.
132. Smalley SL, Asarnow RF, Spence MA: Autism and genetics. Arch Gen Psychiatry 45:953-961, 1988.
133. Smeltzer MD, Curtis JT, Aragona BJ, Wang Z: Dopamine, oxytocin, and vasopressin receptor binding in the medial prefrontal cortex of monogamous and promiscuous voles. Neurosci Lett 394:146-151, 2006.
134. Stavropoulos KK, Carver LJ: Research Review: Social motivation and oxytocin in autism-implications for joint attention development and intervention. J Child Psychol Psychiatry 54:603-618, 2013.
135. Sterne J, Egger M, Moher D. Addressing reporting biases. In: J.P.T. Higgins, S. Green, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley; 2008, pp. 297-334.
136. Strathearn L, Fonagy P, Amico J, Montague PR: Adult attachment predicts maternal brain and oxytocin response to infant cues. Neuropsychopharmacology 34:2655-2666, 2009.
137. Strömland K, Nordin V, Miller M, Akerström B, Gillberg C: Autism in thalidomide embryopathy: A population study. Dev Med Child Neurol 36:351-356, 1994.
138. Su LL, Chong YS, Samuel M: Oxytocin agonists for preventing post-partum haemorrhage. Cochrane Database Syst Rev 3:CD005457, 2007.
139. Suarez MA: Sensory processing in children with autism spectrum disorders and impact on functioning. Pediatr Clin North Am 59: 203-214, 2012.
140. Sucksmith E, Allison C, Baron-Cohen S, Chakrabarti B, Hoekstra RA: Empathy and emotion recognition in people with autism, first-degree relatives, and controls. Neuropsychologia 51:98-105, 2013.
141. Tachibana M, Kagitani-Shimono K, Mohri I, Yamamoto T, Sanefuji W, Nakamura A, Oishi M, Kimura T, Onaka T, Ozono K, Taniike M: Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders. J Child Adolesc Psychopharmacol 23:123-127, 2013.
142. Tchaconas A, Adesman A: Autism spectrum disorders: A pediatric overview and update. Curr Opin Pediatr 25:130-144, 2013.
143. Theodosis DT, Trailin A, Poulain DA: Remodeling of astrocytes, a prerequisite for synapse turnover in the adult brain? Insights from the oxytocin system of the hypothalamus. Am J Physiol Regul Integr Comp Physiol 290:R1175-R1182, 2006.
144. Thompson RR, George K, Walton JC, Orr SP, Benson J: Sex-specific influences of vasopressin on human social communication. Proc Natl Acad Sci USA 103:7889-7894, 2006.
145. Vaccari C, Lolait SJ, Ostrowski NL: Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology 139:5015-5033, 1998.
146. Van Ijzendoorn MH, Bakermans-Kranenburg MJ: A sniff of trust: Meta-analysis of the effects of intranasal oxytocin administration on face recognition, trust to in-group, and trust to out-group. Psychoneuroendocrinology 37:438-443, 2012.
147. Veenema AH: Toward understanding how early-life social experiences alter oxytocin-and vasopressin-regulated social behaviors. Horm Behav 61:304-312, 2012.
148. Werling DM, Geschwind DH: Sex differences in autism spectrum disorders. Curr Opin Neurol 26:146-153, 2013.
149. Windle RJ, Kershaw YM, Shanks N, Wood SA, Lightman SL, Ingram CD: Oxytocin attenuates stress-induced c-fos mRNA expression in specific forebrain regions associated with modulation of hypothalamo-pituitary-adrenal activity. J Neurosci 24: 2974-2982, 2004.
150. Witt DM, Winslow JT, Insel TR: Enhanced social interactions in rats following chronic, centrally infused oxytocin. Pharmacol Biochem Behav 43:855-861, 1992.
151. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA: Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Meta-epidemiological study. BMJ 336:601-605, 2008.
152. Yale University: Oxytocin improves brain function in children with autism. Science Daily; May 19, 2012. Available at http://www.sciencedaily.com/ releases/2012/05/120519213236.htm. Accessed March 25, 2013.
153. Yoshida M, Takayanagi Y, Inoue K, Kimura T, Young LJ, Onaka T, Nishimori K: Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. J Neurosci 29:2259-2271, 2009.
154. Yoshimura R, Kiyama H, Kimura T, Araki T, Maeno H, Tanizawa O, Tohyama M: Localization of oxytocin receptor messenger ribonu-cleic acid in the rat brain. Endocrinology 133:1239-1246, 1993.
155. Zoghbi HY, Bear MF: Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb Perspect Biol 1:4, 2012.